Document is current

Article History

Received: 21 April 2023

Accepted: 19 October 2023

First Online: 22 November 2023

Change Date: 4 December 2023

Change Type: Update

Change Details: In reference 15, “Ishii HFM,” is corrected to “Ishii H, Furuya M,” in this version

Declarations

:

: RN received honoraria from Sanofi, Medtronic Japan, Nippon Boehringer Ingelheim, Takeda Pharmaceutical, KISSEI PHARMACEUTICAL, Novartis Pharma, Eli Lilly Japan, Novo Nordisk Pharma, MSD, Astellas Pharma, and Abbott; and subsidies or donations from Taisho Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, Nippon Boehringer Ingelheim, and Abbott. AS declares that he has no conflict of interest. NA received honoraria from Novo Nordisk Pharma and Eli Lilly Japan. MM received honoraria from Sanofi, Eli Lilly Japan, Novo Nordisk Pharma, Abbott Japan, Sumitomo Pharma, Kyowa Kirin, Nippon Boehringer Ingelheim, and Orizuru Therapeutics; research funding from Novo Nordisk Pharma; and subsidies or donations from Sysmex and Nissui. YT is an employee of Sanofi. HI received honoraria from Novo Nordisk Pharma, Sanofi, Terumo, and Sumitomo Pharma; and subsidies or donations from LifeScan Japan, Novo Nordisk Pharma, Sumitomo Pharma, and Taisho Pharmaceutical.

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and the Helsinki Declaration of 1964 and later versions. This study was approved by the ethics committee of the Nagasaki University Hospital (approval date: December 11, 2018; Approval No. 18052134-2) and each participating site.

: Informed consent was obtained from all participants for being included in the study.